IBRX ImmunityBio, Inc.
IBRX ImmunityBio, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $7.85 · VWAP $6.91 · +32.9% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director + 1 other sold $1.1M, Oct 6
Coverage
IBRX Price Structure
Loading timeframes…
Peers
Every watchlist IBRX belongs to, members best 30-day change first — IBRX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@biotech
@ibb
Reported the quarter ending 2026-06-30: revenue $51M, diluted EPS -$0.22, net income -$230M (SEC filing). Across the print the stock moved +1.4% (close before → first close after).
full note →Against street estimates
How IBRX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about IBRX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 14 days ago · Oct 3
IBRX research tape
74 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.